The objectives of this contract are to provide a facility where the pathogenesis of enteric diseases can be studied and candidate vaccines for these diseases can be evaluated. The contractor will recruit adult volunteers from the community, screen them for appropriate immune status, instruct them about the protocol and its objectives, perform studies on an isolation ward in the hospital, and provide appropriate follow-up for all volunteers. The studies will focus on evaluating vaccines for diseases caused by Escherichia coli, Salmonella species, Shigella species, Vibrio cholerae, Campylobacter species, rotavirus, and other enteric viruses. This facility will also be used to study the mechanisms by which these, and related, organisms cause disease. Specifically, organisms will be genetically altered and tested for their resultant virulence. These molecular pathogenesis studies will help define the biological basis of enteric disease. This facility will also serve as a focus for basic clinical investigation of the mucosal immune system and its role in protection against the diseases cause by enteric organisms.

Project Start
1990-11-30
Project End
1995-11-29
Budget Start
1992-11-30
Budget End
1993-11-29
Support Year
Fiscal Year
1993
Total Cost
Indirect Cost
Name
University of Maryland Baltimore
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
003255213
City
Baltimore
State
MD
Country
United States
Zip Code
21201
Muhsen, Khitam; Lagos, Rosanna; Reymann, Mardi K et al. (2014) Age-dependent association among Helicobacter pylori infection, serum pepsinogen levels and immune response of children to live oral cholera vaccine CVD 103-HgR. PLoS One 9:e83999
Rennels, Margaret B; Deloria, Maria A; Pichichero, Michael E et al. (2002) Lack of consistent relationship between quantity of aluminum in diphtheria-tetanus-acellular pertussis vaccines and rates of extensive swelling reactions. Vaccine 20 Suppl 3:S44-7
Pichichero, M E; Anderson, E L; Rennels, M B et al. (2001) Fifth vaccination with dipthteria, tetanus and acellular pertussis is beneficial in four- to six-year-olds. Pediatr Infect Dis J 20:427-33
Rennels, M B; Deloria, M A; Pichichero, M E et al. (2000) Extensive swelling after booster doses of acellular pertussis-tetanus-diphtheria vaccines. Pediatrics 105:e12
Donnenberg, M S; Tacket, C O; Losonsky, G et al. (1998) Effect of prior experimental human enteropathogenic Escherichia coli infection on illness following homologous and heterologous rechallenge. Infect Immun 66:52-8
Pichichero, M E; Deloria, M A; Rennels, M B et al. (1997) A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children. Pediatrics 100:772-88
Galen, J E; Gomez-Duarte, O G; Losonsky, G A et al. (1997) A murine model of intranasal immunization to assess the immunogenicity of attenuated Salmonella typhi live vector vaccines in stimulating serum antibody responses to expressed foreign antigens. Vaccine 15:700-8
Tacket, C O; Kelly, S M; Schodel, F et al. (1997) Safety and immunogenicity in humans of an attenuated Salmonella typhi vaccine vector strain expressing plasmid-encoded hepatitis B antigens stabilized by the Asd-balanced lethal vector system. Infect Immun 65:3381-5
Barry, E M; Gomez-Duarte, O; Chatfield, S et al. (1996) Expression and immunogenicity of pertussis toxin S1 subunit-tetanus toxin fragment C fusions in Salmonella typhi vaccine strain CVD 908. Infect Immun 64:4172-81
Losonsky, G A; Yunyongying, J; Lim, V et al. (1996) Factors influencing secondary vibriocidal immune responses: relevance for understanding immunity to cholera. Infect Immun 64:10-5

Showing the most recent 10 out of 17 publications